Canada markets closed

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.99-0.03 (-0.09%)
At close: 4:00PM EDT
Sign in to post a message.
  • J
    James
    Robert Coffin, Ph.D., President and Chief Research & Development Officer, will participate in a panel titled ''Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumours'' at the William Blair Biotech Focus Conference taking place virtually on Wednesday, July 14, at 4:20 PM ET.

    A simultaneous webcast will be available in the Investors section. A replay will be available for approximately three months following the conference.
  • R
    RV
    $ZIOP conversation
    Tweet
    See new Tweets
    Conversation
    brendan
    @brendan_49
    ·
    Apr 26
    Many slides like this first one that scream bad news for (non-niche) I/O solid tumor concepts based on antigens that will be shared by many patients.

    TILS like $IOVA, OVs like $REPL are the bridge until you have something like $ZIOP able to ID and transduce patient specific TCRs
    Aaron Rosenblum
    @AaronRosenblum5
    ·
    Apr 26
    Why is the $ziop approach superior to ov/til and what is the timeline for them potentially getting to market.
    brendan
    @brendan_49
    Replying to
    @AaronRosenblum5
    Non-viral transfection of the TCR might make it feasible to construct neoantigen specific engineered T cells on a patient by patient basis. $ZIOP plan is to build shared-neoantigen library first (feasible in certain indications w/ common hotspots). Then personal.

    https://twitter.com/brendan_49/status/1386694920388235272/photo/1
  • C
    Christopher
    Anyone have any thoughts on why this has been crushed the last two days? Was looking like it was ready for a major breakout. Now a disaster. Thanks.
  • J
    James
    Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1. Here is the link shorturl[DOT]at/sDN35
  • J
    James
    As of the end of March, cash, cash equivalents and short-term investments of $476.3M. Based on the current operating plan, the company believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024. The PR shorturl[DOT]at/anL49
  • A
    AC
    Look at their pipeline! This one is going to be huge!! IMHO
  • A
    AC
    No sellers at these prices. They have to bid higher to cover.
  • J
    James
    “Based on the depth and durability of responses and the manageable safety profile we have seen in patients with non-melanoma skin cancers treated with RP1 in combination with Opdivo to date, we are amending the clinical trial protocol for our Phase 2 CERPASS clinical trial to include complete response (CR) rate as a primary endpoint in addition to overall response rate (ORR), and to reduce target enrollment to 180 patients,” said Robert Coffin, Ph.D. “Incorporating CR as an independent additional primary endpoint should ensure a robust assessment of the clinical meaningfulness of adding RP1 to Libtayo in the primary data analysis upon which a BLA submission and FDA’s assessment for approval will be based.”

    Under the modified clinical trial protocol for CERPASS, they plan to add CR rate as an additional independent primary endpoint, in addition to ORR, and to reduce target enrollment from 240 patients to 180 patients. Secondary endpoints will continue to include DOR, PFS, and OS. They maintain guidance and expect initial data next year. The company plans to submit the amended clinical trial protocol to the FDA in the first half of the year.
  • A
    AC
    They have been hiring the talent around big time lately. It looks like preparations before life off.
  • A
    Anonymous
  • A
    Anonymous
    single agent activity of RP2, to be presented at SITC:
    —-
    Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

    Francesca Aroldi, MD, University of Oxford, Joseph Sacco, MSc, MBChB, MRCP, Ph, Kevin Harrington, PhD, FRCP, FRCR, Anna C. Olsson-Brown, MD, Pablo Nanclares, MD, Lavita Menezes, Praveen K. Bommareddy, MS, PhD, Suzanne Thomas, PhD, Howard L. Kaufman, MD, Selda Samakoglu, MD, PhD, Robert S. Coffin, PhD, Mark R. Middleton, MD, PhD

    Background
    RP2 is an enhanced potency oncolytic HSV-1 expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), a fusogenic protein (GALV-GP R-), and an anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody-like molecule which is being tested in an open-label, multicenter, phase 1 study alone and combined with PD-1 blockade (NCT04336241).

    Methods
    The objectives were to assess initial safety and efficacy and determine the recommended phase 2 dose (RP2D) of RP2 alone and combined with nivolumab. Patients were to be treated using a 3+3 dose escalation at two dose levels of up to 10mL of RP2 Q2W up to 5 times (dose level 1: 105 PFU/mL then 4 doses of 106 PFU/mL; dose level 2: 106 PFU/mL then 4 doses of 107 PFU/mL). Following determination of the RP2D, additional HSV-1 seronegative patients were to be enrolled such that ≥3 had been dosed with RP2 at the RP2D, and a combination cohort of up to 30 patients dosed up to 8 times with RP2 at the RP2D combined with nivolumab (240mg Q2W for 4 months from the second RP2 dose, then 480 mg Q4W for 20 months) opened. Lesions were injected directly or under imaging guidance used for visceral lesions. Tumor biopsies were obtained for biomarker analysis. Viral shedding and anti-HSV antibody titers were also monitored.

    Results
    Six HSV seropositive patients were enrolled in the dose-escalation phase with primarily Grade 1-2 adverse events, including febrile and other constitutional symptoms, local inflammation, and erythema observed. There were no DLTs requiring dose level expansion. The RP2D was selected as up to 10mL of 106 PFU/mL followed Q2W by multiple doses of 107 PFU/mL. Of the six patients treated with single agent RP2, three (50%) have ongoing partial responses. Objective responses (including in uninjected tumors) were observed in patients with uveal melanoma (prior ipilumumab/nivolumab; extensive liver metastases), mucoepidermoid carcinoma (prior carboplatin/paclitaxel, bicalutamide, ceralasertib), and esophageal cancer (prior durvalumab, M6620, capecitabine, oxaliplatin, cisplatin, chemoradiation; liver and abdominal node metastases). Enrollment is underway in HSV seronegative patients and in combination with nivolumab. Updated data including biomarker and biodistribution data will be presented.

    Conclusions
    The Phase 1 clinical data supports the safety and efficacy of single agent RP2, including demonstration of uninjected tumor response in patients with difficult to treat advanced cancers. This data supports the hypothesis that anti-CTLA-4 delivered intra-tumorally through oncolytic virus replication, with accompanying antigen release and presentation, can provide potent anti-tumor effects.
  • A
    Anonymous
    From the latest public offering-related SEC filing (June 8, 2020):

    "Based on the data generated to date, we have decided to amend the protocol to allow for an expansion of the second part of this clinical trial (of RP2 combined with nivolumab) from 12 to 30 patients."

    So they have seen some activity - would be interesting to learn which tumor types. Data to be released in H2/2020 - maybe July 1!?!
  • T
    Tartiaboy
    Just listened to the JP Morgan presentation: RP-1 CSCC data is phenomenal; likely three pivotal trials will be running by later this year.

    I don't think most people really understand what REPL means when they say that their technology is targeted to be a new corner stone of IO. I consider this my safest onco-biotech play, because the approach is already proven to work.

    Be First, be right (be patient).
  • J
    James
    The company will host an investor event to present updated data from its PhII skin cancer cohorts combining RP1 with Opdivo and data from its PhI trial of RP2 alone and in combination with Opdivo. The event will include presentations by Philip Astley-Sparke, Chief Executive Officer, Robert Coffin, Ph.D., President and Chief Research & Development Officer, and Professor Mark Middleton.

    The event will begin at 8:00 a.m. Eastern Time on Thursday, June 3. The webcast and slides will be accessible live under “Events & Presentations” on the Investors page of the company's website.
  • J
    James
    ASCO-GI: A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.

    Background: Pancreatic ductal adenocarcinoma (PDAC) has been highly resistant to immunotherapeutics to date. LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L and 4-1BBL, has been shown to lyse tumor cells selectively, induce anti-tumor cytotoxic T-cell responses, reduce myeloid-derived suppressor cell (MDSC) infiltration, and induce tumor regression in preclinical studies.

    Methods: In this phase I/II trial, patients with unresectable or metastatic PDAC are treated with LOAd703 intratumoral injections and standard nab-paclitaxel/gemcitabine (nab-P/G) chemotherapy. Starting on cycle 1 day 15 of nab-P/G, LOAd703 is injected with image guidance into the primary pancreatic tumor or a metastasis every 2 weeks for 6 injections. In the event of sustained tumor control, subjects are eligible to receive 6 more injections. Three dose levels of LOAd703 are being investigated using a BOIN dose escalation design. Primary endpoints are safety and feasibility. Secondary endpoints include response rate and overall survival.
  • E
    Eren
    What a great board with sound scientific argumentation from the posters. I have done my DD on this under the radar gem and already profiting after starting a position weeks ago. I like their science (Have been a scientist for more than 10 years) and have been investing in bios for over eight years. There is just one thing I can’t put my finger on. Obviously it’s a clinical stage company with no products yet so after doing some mathe how come the valued market cap currently is about 2 billion with no revenue streams what am I missing here ? I know the board and CEO and their management setup but looking at other clinical stage companies their valuation is set at between 750 millions to slightly under 1.2 billions or so. Any input is appreciated btw buying more today at market open.
  • T
    Tartiaboy
    The key to valuing REPL is not in the efficacy of any one product, it's in understanding the break-though in viral oncology. This is a new platform that has already been proven with Tvec. RP1, RP2 and RP3 are new enhanced iterations. REPL is not limited to these three products.

    Knowledge is power. Do your DD.
  • J
    James
    Members from the company's management team will present and host one-on-one meetings at the following three virtual investor conferences.

    H.C. Wainwright Global Life Sciences Conference
    Date: March 9-10, 2021
    Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, at 7:00 am ET

    Barclays Global Healthcare Conference
    Date: Thursday, March 11
    Fireside Chat Presentation Time: 9:10 am ET

    33rd Annual Roth Conference
    Date: Wednesday, March 17
    Presentation Time: 1:30 pm ET

    A simultaneous webcast of the fireside chat presentation at the Barclays Global Healthcare Conference will be available in the Investors section of website. A replay will be available for approximately 90 days following the conference.
  • J
    James
    RP1 SITC abstract results: ''As of 24th June 2020, 36 melanoma and 16 NMSC patients had been enrolled with follow up of <1-17 months. Of the melanoma patients, 16 previously antiPD1 treated cutaneous (8 also prior anti-CTLA-4), 8 anti-PD1 naïve cutaneous, 6 mucosal, and 6 uveal. Of the NMSC patients, 10 had squamous cell (CSCC), 3 had a basal cell, 1 had Merkel cell carcinomas, and 2 had angiosarcoma. Treatment emergent adverse events (TEAEs) remain consistent with phase 1, with RP1 side effects generally of Grade 1/2 constitutional-type symptoms, with no exacerbation of the side effects expected for nivolumab. At the data cut-off, 5 previously anti-PD1 treated (4 also anti-CTLA-4) cutaneous melanoma patients, 4 anti-PD1 naïve cutaneous melanoma patients, two mucosal melanoma patients (one anti-PD1 refractory) and one uveal melanoma patient (ipi/nivo refractory) have achieved response (WHO criteria for uveal). For NMSC, for the 13 patients with >8 weeks follow up, one of two angiosarcoma patients and seven of eight CSCC patients (5 CR) have achieved response (CSCC ORR 87.5%; CR rate 62.5%, including of uninjected visceral disease). Tumor biopsies in patients continue to routinely show immune activation, including robust recruitment of CD8+ T cells, reversal of T cell exclusion, and increased PD-L1 expression. Treatment remains ongoing, and current data will be presented.''
  • J
    James
    The company have announced that Robert Coffin, Ph.D., CEO and Director, will present at the 38th Annual J.P.Morgan Healthcare Conference on Tuesday, January 14, at 5:00 PM PT at the Westin St. Francis Hotel in San Francisco, CA.